News
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 3, 2017Conference Call and Live Webcast at 8:30am Eastern Time
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and nine months...
-
Sep 27, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases announced today that it will be presenting at the 2017...
-
Aug 15, 2017Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the second quarter ending June...
-
Aug 14, 2017Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the second quarter ending June...
- Aug 10, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and six months ended
-
Aug 7, 2017Mary Kay Turner brings 25+ years Biotech and Pharmaceutical Experience in Healthcare Advocacy and Policy; Prior Positions Include Head of Patient Advocacy and Communications at Mitsubishi Tanabe Pharma America and Head of State Government Affairs and Advocacy at Bristol-Myers Squibb Company
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointment of Mary Kay Turner to the...
-
Jul 25, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a definitive agreement with the
-
Jul 21, 2017
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the California Institute for Regenerative...
-
Jul 18, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed definitive agreements with...
-
Jul 3, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has selected Worldwide Clinical Trials...
-
Jun 14, 2017
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company will present a corporate...
- Jun 13, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm...
- May 22, 2017
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the Company will present data from its Phase 2...
- May 16, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has begun training the cell...
- May 15, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the first quarter ending March...
-
May 1, 2017
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present data from its...
- Apr 20, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer,...
-
Apr 19, 2017Preclinical Findings Show Potential for Human Benefit
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that a preclinical study evaluating the use of...
Mar 30, 2017BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the year ended December 31,...
- Mar 22, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer,...
Mar 6, 2017Brings 10+ years Biotech and Pharmaceutical Industry Experience; Prior Academic Positions Include Consultant Neurologist Role at Mount Sinai Hospital, Toronto, Canada.BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointment of Ralph Z. Kern, MD, MHSc to...
-
Mar 1, 2017Tel Aviv Sourasky Medical Center (Ichilov) Is Also Expected to be a Treatment Center in Planned Phase 3 Trial of NurOwn In ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that is has signed a Memorandum of...
- Feb 27, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointments of June S. Almenoff, M.D.,...
- Feb 21, 2017
Signs agreement with CCRM for regulatory support of ALS treatment TORONTO, HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 21, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:...
- Feb 16, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it plans to contract with City of Hope's...
